Collaborations between CROs and CDMOs are on the rise, empowering the newly formed entities to provide even more capabilities to their biopharma partners. But what was initially considered to be a transient industry trend is now proving itself to be a sweeping paradigm shift. So, what’s the ultimate impact on patients? Thermo Fisher Scientific’s new trend report in collaboration with CPHI explores how CRO/CDMO collaborations are moving the needle in a brighter, more patient-centric direction.
Transforming CDMO Partnerships Through Quality
Get an in-depth look into key indicators of CDMO quality, with tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.View Infographic
What is a CDMO? Seven things to look for in a quality CDMO partner
Learn how CDMOs (contract development and manufacturing organizations) work with pharma companies, and the top considerations companies have when choosing a CDMO partner.Read Blog
CROs vs CMOs, and CDMOs: What’s the difference between the three?
CROs, CMOs, and CDMOs all help biotechnology and pharmaceutical companies with drug development and manufacturing, but what’s the difference between the three?Read Blog
Optimizing the cell therapy patient journey through integrated CRO CDMO partnership
Watch this on-demand webinar for insights on how working with a single integrated CRO/CDMO partner can help ease industry challenges and provide an accelerated path from development to manufacturing, as well as the benefits that come from unified teams and infrastructure.
CDMO Checklist to Launch Your Molecule Globally
Preparing to take your drug into the global market? You’ll need to make sure your CDMO has what it takes to successfully navigate the global regulatory space with speed, security, and supply safeguards. Use this quick list as a reference when evaluating your options.View Infographic
Enabling a digital culture through integrated business processes
In contrast to a physical work environment, where stability and experience are key, a digital business environment focuses on innovation and connectivity. Learn more.
The changing landscape of oncology drug development: Bringing novel lifesaving therapies to patients
Oncology is the fastest-growing, most active sector of drug development. Matching drug products to clinical and commercial needs requires scientific and technological innovation.View Whitepaper
Protecting tomorrow: Supporting sustainability in the pharmaceutical and biotech industries
Learn how Thermo Fisher is meeting its environmental sustainability goals, and how we work in partnership with the pharma and biotech communities on shared environmental sustainability goals.View eBook
Preparing biologics for commercialization: Understanding Strategies to Reduce Risk and Optimize Outcomes in Drug Development
Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product. Different players step in during each point, so keeping a program with many moving parts on track requires planning and time-tested execution approaches.View Infographic
Advancing drug development using in silico modeling
This report provides a framework for that understanding by outlining some of the processes that stand to gain the most from computational modeling and identifying the in silico capabilities that can be used to accelerate and de-risk each phase of development.Read Whitepaper